Dayvigo Improves Sleep Factors in Patients with COPD

Study results presented at the 2024 SLEEP meeting of the Associated Professional Sleep Societies demonstrated that Dayvigo (lemborexant; Easai, Woodcliff, NJ), a dual-orexin receptor antagonist Food and Drug Administration (FDA)-approved for the treatment of insomnia in adults, improved sleep onset, sleep maintenance, and total sleep time (TST) in participants with untreated moderate-to-severe chronic obstructive pulmonary disease (COPD).

Post hoc analysis of the double-blind, placebo-controlled, crossover study (NCT04647383) included 30 adults aged 45-90 years (mean age 69.2 years) with untreated moderate (n=25) or severe (n=5) COPD assessed by Global Initiative for Obstructive Lung Disease spirometry recommendations. Participants were randomized to receive Dayvigo 10 mg or placebo in two 8-night treatment periods, separated by at least 14 days. Researchers used in-laboratory polysomnography to assess latency to persistent sleep (LPS), sleep efficiency, wake after sleep onset (WASO), and TST, on days 1 and 8.

Participants receiving Dayvigo treatment showed significant improvements in the following sleep factors vs placebo treatment:

• LPS on day 1 (30.9 vs 51.5 min, P<0.01) and day 8 (27.0 vs 46.6 min, P<.001).
• Sleep efficiency on day 1 (81.0% vs 66.6%, P<.0001) and day 8 (77.1% vs 69.4%, P<.0001).
• WASO on day 1 (68.2 vs 114.6 min, P<.0001) and day 8 (90.4 vs 106.1 min, P<.0001).
• TST on day 1 (388.9 vs 319.5 min, P<0.0001) and day 8 (370.1 vs 332.9 min, P<.0001).